None listed
Conditions
Interventions
Drug : 3 GBH or placebo granule(1.5g for each, total 4.5g) are orally administered two times a day, for 8 weeks
Sponsors
Korea Institute of Oriental Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Men and women aged 19 to 65 2. Those diagnosed with major depressive disorder in DSM-V(Diagnostic and Statistical Manual of Mental Disorders-5) 3. Those with a K-HDRS(Korean Version of the Hamilton Depression Rating Scale) score of 18 or higher 4. Those who voluntarily decide to participate and sign the agreement.
Exclusion criteria
Exclusion criteria: 1. Participant with a risk of suicide 2. Participant with major depressive disorder who need hospitalization treatment 3. Participant who received electroconvulsive therapy (ECT), vagal nerve stimulation (VNS), deep brain stimulation (DBS), light therapy, or transcranial magnetic stimulation (TMS) within three months 4. Participant who are diagnosed and being treated as a panic disorder, obsessive disorder, post traumatic stress disorder, or personality disorder 5. Participant with a history of manic, schizophrenic, or mixed episode 6. Participant with a current or lifetime alcohol or other substance abuse/dependence 7. Participant who are taking medicines or substances that may affect the degree of depression (eg. anxiolytics, antidepressants, antipsychotics, corticosteroids, female hormones, L-dopa, Digitalis, bromide, cyclosporin, disulfiram, isoniazid, yohimbine) within 4 weeks 8. Participant who taking antiplatelet agents 9. Participant with a medical condition that may affect the degree of depression (eg. myocardial infarction, brain tumor, multiple sclerosis, pancreatic disease, hypo/hyperthyroidism, hyperparathyroidism, Addison's disease, Cushing's disease, rheumatoid arthritis, Cancer, cerebrovascular disease, dementia, epilepsy, etc.) 10. Participant with chronic illnesses that are not well controlled with proper treatment (chronic active hepatitis, hypertension, diabetes, etc.) 11. Participant who are being treated for liver cancer, liver cirrhosis, chronic kidney failure, or who are being treated with congestive heart failure classified as NYHA Class III-IV 12. Participant with liver dysfunction or renal impairment (ALT, AST, ALP = twice the normal upper limit or creatinine > 2.0 mg/dL at screening) 13. Participant with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption 14. Participant who has a disease that may affect the absorption of the drug or who has a digestive disorder after surgery 15. Participant who participated in the other clinical trials within 1 month 16. Participant with hypersensitivity reactions and allergies to research drugs 17. Participant who are taking other herbal medicines 18. Participant who are unable to understand the consent form due to mental retardation or intellectual problems 19. Pregnant or lactating women 20. Participant who are likely to be pregnant and who do not agree to the approved methods of contraception (double contraception, intrauterine contraceptive, and spermicide) during the trial 21. Participant who are determined to be unsuitable by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Korean Version of the Hamilton Depression Rating Scale (K-HDRS) - Change in total score | — |
Secondary
| Measure | Time frame |
|---|---|
| Korean Version of the Hamilton Depression Rating Scale (K-HDRS) - Change in total score;Korean Version of the Hamilton Depression Rating Scale (K-HDRS) - Percentage of subjects whose overall score improved by more than 50%;Korean Version of the Hamilton Depression Rating Scale (K-HDRS) - Percentage of subjects who improved to less than 7 points;The Korean version of the Beck Depression Inventory-? (K-BDI-?);Korean version of Symptom Checklist-95-Revision (KSCL-95);Insomnia Severity Index (ISI);State-Trait Anxiety Inventory-Korean version (STAI-K);State-Trait Anger Expression Inventory-Korean version (STAXI-K);Pattern Identifications Tool for Depression (PITD);EuroQol-5 dimension (EQ-5D);Melatonin & Cortisol;Adverse event | — |
Countries
Korea, Republic of
Contacts
Public ContactYujin Choi
Korea Institute of Oriental Medicine
Outcome results
None listed